Meduslabs — Evidence-based health research
Home›Cancer›Lymphoma: Symptoms, Types, Treatment, and Immune Support
Key Takeaways

The lymphatic system is part of the immune system, responsible for clearing toxins. Lymphoma develops when cells in the lymphatic system become altered and start to multiply uncontrollably. Although it arises from the lymphatic system, lymphoma can spread through the blood to other parts of the body and cause blood-related symptoms such as anaemia, low white-blood-cell counts, bleeding or bruising.

Lymphoma symptoms

Lymphoma symptoms can vary widely and depend on the type of lymphoma. The most common are:

Types of lymphoma

There are several types of lymphoma, which differ in how they progress and how they are treated. The two main categories are Hodgkin lymphoma and non-Hodgkin lymphoma.

Hodgkin lymphoma is a rarer form of lymphoma, but it is more treatable than non-Hodgkin lymphoma. It presents as damage to the lymph nodes, and it is very important to begin treatment as early as possible to prevent further spread.

Non-Hodgkin lymphoma is the more common form and is harder to treat than Hodgkin lymphoma. It also presents as lymph-node involvement and can spread to other organs, so timely treatment is especially important here too.

Lymphoma treatment

Treatment depends on the type and severity of the disease. The most common approaches are chemotherapy, radiotherapy, and supportive (adjunctive) care.

Chemotherapy is one of the most frequently used treatments for lymphoma. It involves special medications that destroy cancer cells. A course of chemotherapy can last several months and may cause side effects such as fatigue, headache, nausea and vomiting. Radiotherapy is another common treatment, applying radiation to the cancerous area to destroy cancer cells. A course can last several weeks and may cause side effects such as skin redness and itching.

Can I help myself further?

You need to balance your diet and the other factors that only YOU can control. This helps the immune system work more effectively, and makes cancer treatment (such as chemotherapy) even more effective. With natural immune-system modulators (such as Lentinan), you can help the immune system fight cancer cells. We also recommend breathing exercises following the Wim Hof method, and physical activity. Cancer knows how to send cloaking signals, so the immune system finds it hard to detect — concentrated mushroom-polysaccharide formulas are studied for their role in strengthening the immune response during oncological disease.

Related supplement

Lymphoma cells evade immune detection with cloaking signals. Concentrated mushroom polysaccharides are studied for their role in strengthening the immune response alongside treatment.

Lentinan AXT by Zenius Labs™ →
What are the symptoms of lymphoma?

Symptoms vary by type but commonly include enlarged lymph nodes, abdominal pain, fever, skin rashes, weight loss, and bleeding. Because lymphoma can spread through the blood, it may also cause anaemia, low white-blood-cell counts and bruising.

What is the difference between Hodgkin and non-Hodgkin lymphoma?

Hodgkin lymphoma is the rarer form but more treatable. Non-Hodgkin lymphoma is more common and harder to treat, and can spread to other organs. Both present as lymph-node involvement, and timely treatment is important for both.

Can you support the immune system during lymphoma treatment?

Yes. Balancing diet and lifestyle helps the immune system work more effectively alongside treatment such as chemotherapy. Concentrated mushroom-polysaccharide formulas, such as Lentinan AXT by Zenius Labs™, are studied for their role in supporting the immune response during oncological disease.

References
  1. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and …. PubMed
  2. Evolving molecular classification of aggressive B-cell lymphoma. PubMed
  3. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. PubMed
  4. Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
  5. Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
  1. Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
  2. Zhou X et al. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The oncologist. 2008. PubMed
  3. Li B et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2006. PubMed
  4. Xia Y et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of immunology (Baltimore, Md. : 1950). 1999. PubMed
  5. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  6. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  7. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  8. Adachi Y et al. Potentiation of Antitumor Activity by Antibody Drugs and Mushroom-Derived β-Glucans in Natural Killer Cell-Mediated Tumoricidal Activities against Non-Hodgkin’s B-Cell Lymphoma. International journal of medicinal mushrooms. 2023. PubMed
  9. Sam J et al. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025. PubMed
  10. Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England journal of medicine. 2015. PubMed
  11. Azoulay T et al. Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression. Cancer immunology, immunotherapy : CII. 2023. PubMed
  12. Sato A et al. [Pathogenesis and novel therapy for EBV-related B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2016. PubMed
  13. Chen J et al. Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas. Discover oncology. 2025. PubMed
  14. Liquidano-Perez E et al. Case Report: Hydroa vacciniforme-like lymphoproliferative disorder, an EBV-associated disease, successfully treated with hematopoietic stem cell transplantation. Frontiers in immunology. 2025. PubMed
  15. Song JY et al. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma. Haematologica. 2023. PubMed
  16. Greenbaum AM et al. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling. Blood research. 2022. PubMed
  17. Liu WR et al. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017. PubMed
  18. Wang D et al. Dectin-1 stimulates IL-33 expression in dendritic cells via upregulation of IRF4. Laboratory investigation; a journal of technical methods and pathology. 2018. PubMed
  19. Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology. 2013. PubMed
  20. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  21. Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
  22. Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
  23. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  24. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  25. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  26. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  27. van der Meer JW et al. Trained immunity: A smart way to enhance innate immune defence. Molecular immunology. 2015. PubMed
  28. Vuscan P et al. Potent induction of trained immunity by Saccharomyces cerevisiae β-glucans. Frontiers in immunology. 2024. PubMed
  29. Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed
  30. Liu F et al. The mechanisms for the radioprotective effect of beta-d-glucan on high linear-energy-transfer carbon ion irradiated mice. International journal of biological macromolecules. 2019. PubMed
  31. Christophersen OA Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure. Microbial ecology in health and disease. 2012. PubMed
  32. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  33. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  34. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
Zenius Labs™

Lentinan AXT — concentrated immune-support formula

Lentinan AXT by Zenius Labs™ combines Lentinus edodes and Coriolus versicolor polysaccharides with astaxanthin in a concentrated, precision formula — designed to strengthen the immune response during oncological disease.

Get Lentinan AXT